☆ 4.7 Article

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM)

ANNALS OF ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Alex Friedlaender et al.

Summary: Classic activating mutations in EGFR and HER2 are predictive of response to targeted therapies, while insertion mutations in exon 20 of either gene are generally less sensitive to treatment. Novel therapeutic strategies are being developed to effectively target tumors driven by these non-classic mutations.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation

Laszlo Urban et al.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Review Oncology

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Antonio Passaro et al.

Summary: The first-line treatment for NSCLC patients with EGFR mutations is an EGFR TKI, but some patients have uncommon mutations with varying sensitivities to different TKIs, complicating treatment decisions. Recent studies have integrated data on the activity of different TKIs against major uncommon EGFR mutations and proposed treatment strategies for these cases.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Sabine Zoechbauer-Mueller et al.

Summary: This study describes a rare case of a lung adenocarcinoma patient with an EGFR exon 20 insertion who has been treated with afatinib for 4.5 years, demonstrating potential efficacy of afatinib for this rare mutation. While two other rare EGFR mutation cases were reported, one patient did not experience long-term benefit due to disease progression.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial

Caicun Zhou et al.

Summary: This study evaluated the treatment outcomes and safety of mobocertinib in patients with previously treated EGFRex2Oins-positive mNSCLC, showing clinically meaningful benefit and manageable safety profile in this patient population.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park et al.

Summary: Amivantamab demonstrates robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations, even after progression on platinum-based chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne P. Robichaux et al.

Summary: The study characterized the mutational landscape in 16,715 patients with EGFR-mutant NSCLC and established the structure-function relationship of EGFR mutations on drug sensitivity. EGFR mutations can be separated into four distinct subgroups based on sensitivity and structural changes, predicting patient outcomes following treatment with EGFR inhibitors better than traditional exon-based groups. This structure-based approach delineates functional groups of EGFR mutations that can effectively guide treatment choices and suggest potential improvement in prediction of drug sensitivity to targeted therapies in oncogenes with diverse mutations.

NATURE (2021)

添加到收藏夹

Review Oncology

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates

Catherine B. Meador et al.

Summary: EGFR ins20 mutations, occurring in approximately 10% of EGFR-activating mutations, have historically shown reduced sensitivity to early-generation EGFR TKIs. However, recent advancements in scientific understanding and clinical detection techniques have improved our ability to develop effective therapies for this subset of EGFR-mutant NSCLC.

CANCER DISCOVERY (2021)

添加到收藏夹

Review Oncology

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

Peter T. Harrison et al.

SEMINARS IN CANCER BIOLOGY (2020)

添加到收藏夹

Article Oncology

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Jang Ho Cho et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

James Chih-Hsin Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

Julia Roeper et al.

Oncotarget (2020)

添加到收藏夹

Article Oncology

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

Antonio Passaro et al.

CLINICAL LUNG CANCER (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Simon Vyse et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)

添加到收藏夹

Article Oncology

Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations

Christina Alidousty et al.

JOURNAL OF PATHOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

J. Mateo et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

A. Kron et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Precision oncology based on omics data: The NCT Heidelberg experience

Peter Horak et al.

INTERNATIONAL JOURNAL OF CANCER (2017)

添加到收藏夹

Review Medicine, General & Internal

Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Oncology

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Yoshihisa Kobayashi et al.

CANCER SCIENCE (2016)

添加到收藏夹

Article Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James C-H Yang et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer

Miguel A. Molina-Vila et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi-Long Wu et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Lecia V. Sequist et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell et al.

LANCET ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi et al.

LANCET ONCOLOGY (2010)

添加到收藏夹

Article Medicine, General & Internal

Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.

Tony S. Mok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.